Skip to main content

Table 1 Features of patients included in the derivation data set (Auckland) and the independent validation data set (Waikato)

From: Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index

 

Derivation (Auckland)

Validation (Waikato)

Total number of women with invasive cancer

10,586

3071

Number of complete cases

9182

2625

Number of deaths due to breast cancer

864

282

Median follow-up time (in months)

67.6

68.4

Age (mean in years)

56.9

59.3

Tumour grade

 Well differentiated

2229 (24%)

624 (24%)

 Moderately differentiated

4108 (45%)

1406 (53%)

 Poorly differentiated

2845 (31%)

595 (23%)

Tumour size (mean in mm)

23.9

22.4

Mean number of positive lymph nodes removed

2.4

1.9

Stage of tumour

 Stage 1

3990 (43%)

1071 (41%)

 Stage 2

3602 (39%)

1117 (42%)

 Stage 3

1432 (16%)

391 (15%)

 Stage 4 (presence of metastasis)

158 (2%)

46 (2%)

ER status

 Negative

1914 (21%)

410 (16%)

 Positive

7268 (79%)

2215 (84%)

PR status

 Negative

2919 (32%)

903 (34%)

 Positive

6270 (68%)

1722 (66%)

HER2 status

 Positive

1156 (13%)

378 (14%)

 Negative/equivocal

6331 (69%)

1750 (67%)

 Test not done

1695 (18%)

497 (19%)

Histological type of tumour

 Ductal

7469 (81%)

2130 (81%)

 Lobular

1072 (12%)

294 (11%)

 Mixed

641 (7%)

201 (8%)

Lymphovascular invasion status

 Negative

6730 (73%)

1939 (74%)

 Positive

2452 (27%)

686 (26%)

Ethnicity

 Maori

720 (8%)

388 (15%)

 Pacific

682 (7%)

40 (2%)

 European NZ

6527 (71%)

2131 (81%)

 Other

1253 (14%)

66 (2%)

  1. Data collection on HER2 status started in 2006